Danske Bank A S Has $133.60 Million Stock Holdings in McKesson Corporation $MCK

Danske Bank A S lessened its position in McKesson Corporation (NYSE:MCK) by 1.3% during the fourth quarter, Holdings Channel reports. The institutional investor owned 162,868 shares of the company’s stock after selling 2,155 shares during the quarter. Danske Bank A S’s holdings in McKesson were worth $133,599,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. GGM Financials LLC acquired a new stake in McKesson in the 3rd quarter valued at approximately $25,000. State of Wyoming bought a new position in McKesson in the second quarter valued at approximately $29,000. Hopwood Financial Services Inc. bought a new position in McKesson in the third quarter valued at approximately $31,000. Vermillion & White Wealth Management Group LLC bought a new position in McKesson in the third quarter valued at approximately $33,000. Finally, Board of the Pension Protection Fund bought a new position in McKesson in the fourth quarter valued at approximately $33,000. Institutional investors and hedge funds own 85.07% of the company’s stock.

Key McKesson News

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: William Blair initiated coverage with an Outperform rating, calling McKesson’s business a “durable competitive moat” and highlighting specialty-led growth upside — a catalyst for improved investor sentiment and support for McKesson’s premium valuation. William Blair Starts McKesson at Outperform
• Positive Sentiment: McKesson Canada won a national distribution agreement with naturemary, expanding retail reach into thousands of pharmacies — a small but tangible example of continued distribution wins that support recurring revenue. naturemary Secures National Distribution with McKesson Canada
• Neutral Sentiment: Analysts are re‑examining McKesson’s valuation around biosimilars and co‑manufacturing optionality; fair‑value estimates changed only marginally, suggesting upside remains tied to execution on specialty and biosimilar initiatives. Watch pipeline and margin signals. Narrative On McKesson Shifting Around Biosimilars And Valuation Premium
• Neutral Sentiment: McKesson sold its stake in Medical‑Surgical Solutions — a portfolio reshaping move that could free capital or simplify operations, but is unlikely to materially change near‑term earnings. McKesson sells stake in Medical-Surgical Solutions
• Negative Sentiment: Pre‑earnings coverage (Yahoo/Zacks) flags McKesson lacks the “right combination” of factors to produce an earnings beat in the upcoming report, increasing downside risk into the print and making the stock vulnerable to disappointment. McKesson Earnings Expected to Grow: What to Know Ahead of Next Week’s Release Zacks Earnings Preview
• Negative Sentiment: Recent coverage noted McKesson shares fell more sharply than the broader market, reflecting short‑term selling pressure that can amplify downside around cautious headlines or an underwhelming earnings print. McKesson Falls More Steeply Than Broader Market

Analysts Set New Price Targets

A number of research firms have weighed in on MCK. UBS Group decreased their price target on McKesson from $1,012.00 to $1,000.00 and set a “buy” rating for the company in a research note on Wednesday, April 22nd. William Blair began coverage on McKesson in a research note on Tuesday. They issued an “outperform” rating for the company. Bank of America decreased their price target on McKesson from $1,040.00 to $1,000.00 and set a “buy” rating for the company in a research note on Monday, April 6th. Morgan Stanley restated an “overweight” rating and issued a $966.00 price target on shares of McKesson in a research note on Thursday, January 29th. Finally, Leerink Partners restated an “outperform” rating and issued a $1,085.00 price target on shares of McKesson in a research note on Thursday, March 5th. Fourteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $972.27.

Insiders Place Their Bets

In related news, Director Maria Martinez sold 349 shares of the business’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $939.87, for a total value of $328,014.63. Following the completion of the sale, the director directly owned 301 shares in the company, valued at $282,900.87. The trade was a 53.69% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Michele Lau sold 2,725 shares of the business’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $990.00, for a total value of $2,697,750.00. Following the completion of the sale, the executive vice president owned 3,247 shares of the company’s stock, valued at $3,214,530. This trade represents a 45.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 3,592 shares of company stock valued at $3,518,555. 0.08% of the stock is owned by insiders.

McKesson Trading Down 0.9%

Shares of NYSE MCK opened at $815.20 on Friday. McKesson Corporation has a 12 month low of $637.00 and a 12 month high of $999.00. The stock has a 50 day moving average of $894.86 and a 200-day moving average of $859.16. The company has a market capitalization of $99.85 billion, a P/E ratio of 23.45, a P/E/G ratio of 1.19 and a beta of 0.42.

McKesson (NYSE:MCK) last issued its earnings results on Wednesday, February 4th. The company reported $9.34 EPS for the quarter, topping the consensus estimate of $9.19 by $0.15. McKesson had a negative return on equity of 338.97% and a net margin of 1.09%.The company had revenue of $106.16 billion during the quarter, compared to the consensus estimate of $105.98 billion. During the same period in the previous year, the company posted $8.03 EPS. The firm’s revenue for the quarter was up 11.4% compared to the same quarter last year. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. Analysts predict that McKesson Corporation will post 39.02 EPS for the current fiscal year.

McKesson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 1st. Stockholders of record on Monday, June 1st will be paid a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Monday, June 1st. McKesson’s payout ratio is currently 9.43%.

McKesson Company Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.